Article Text

PDF
CASE REPORT
Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist’s perspective
  1. Louise Price1,2,
  2. Patricia Glynn1,
  3. Anjali Zarkar1
  1. 1 The Cancer Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK
  2. 2 The Deanesly Centre, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK
  1. Correspondence to Dr Louise Price, louise.price12{at}nhs.net

Summary

A wide variety of cytotoxic medications cause interstitial lung disease (ILD). For the first time, we describe ILD in an 82-year-old woman with muscle invasive bladder cancer 10 days after receiving cetuximab as part of a novel trial. She had no significant medical history or drug allergies, had good exercise tolerance and a 5 pack-year smoking history. She received neoadjuvant chemotherapy (gemcitabine, cisplatin) with a good response on MRI. She was eligible for a phase 2 trial of cetuximab with chemotherapy and radiotherapy for muscle invasive bladder cancer (TUXEDO), in which the trial arm used cetuximab plus standard chemoradiotherapy to the bladder (64 grey in 32 fractions plus mitomycinandfluorouracil). Ten days after her third infusion of cetuximab, she was presented with type 1 respiratory failure. Thoracic CT scan demonstrated new widespread ground glass change in the lungs. She received high-dose steroids (prednisolone 1 mg/kg), broad spectrum antibacterial cover and non-invasive ventilation. She survived to be discharged with residual respiratory failure.

  • chemotherapy
  • radiotherapy
  • urological cancer
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors The case was identified by both LP and AZ. Article was written by LP and critical revision of the article was done by PG and AZ. AZ was responsible for the final approval of the version to be published.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.